We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View
Read MoreHide Full Article
Tarrytown, NY based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. Meanwhile, Regeneron received a major boost when its PCSK9 inhibitor, Praluent, which the company has co-developed with Sanofi, gained approval in the U.S. The cholesterol management market represents huge commercial potential and Praluent is expected to generate blockbuster sales.
In this scenario, investor focus should remain on the performance of Eylea and Praluent apart from the usual top-and bottom-line numbers.
Regeneron’s performance so far has been mixed. In the last four reported quarters, the company has surpassed earnings estimates on two occasions while it missed in the other two. Overall, the company has recorded an average negative earnings surprise of 0.06%.
Currently, Regeneron has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s second-quarter 2016 earnings surpassed expectations. Our consensus called for EPS of $1.73 and the company reported EPS of $2.10 (including share-based compensation expenses and tax adjustments).
Revenues: However, revenues in the reported quarter fell marginally short of expectations. Regeneron posted revenues of $1.21 billion, compared to our consensus estimate of $1.25 billion.
Key Stats: Regeneron’s revenues increased 21% year over year, benefiting from strong Eylea sales. Regeneron reiterated Eylea U.S. net sales guidance for 2016. The company continues to expect U.S. Eylea net sales to grow 20–25% year over year.
Check back later for our full write up on this Regeneron earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View
Tarrytown, NY based Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of products for the treatment of serious medical conditions including eye diseases, high LDL cholesterol. Currently, the company has three marketed products in its portfolio – Eylea, Arcalyst and Praluent.
Eye drug, Eylea, should continue to remain the key growth driver contributing significantly to the top line. Meanwhile, Regeneron received a major boost when its PCSK9 inhibitor, Praluent, which the company has co-developed with Sanofi, gained approval in the U.S. The cholesterol management market represents huge commercial potential and Praluent is expected to generate blockbuster sales.
In this scenario, investor focus should remain on the performance of Eylea and Praluent apart from the usual top-and bottom-line numbers.
Regeneron’s performance so far has been mixed. In the last four reported quarters, the company has surpassed earnings estimates on two occasions while it missed in the other two. Overall, the company has recorded an average negative earnings surprise of 0.06%.
Currently, Regeneron has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Regeneron’s second-quarter 2016 earnings surpassed expectations. Our consensus called for EPS of $1.73 and the company reported EPS of $2.10 (including share-based compensation expenses and tax adjustments).
Revenues: However, revenues in the reported quarter fell marginally short of expectations. Regeneron posted revenues of $1.21 billion, compared to our consensus estimate of $1.25 billion.
Key Stats: Regeneron’s revenues increased 21% year over year, benefiting from strong Eylea sales. Regeneron reiterated Eylea U.S. net sales guidance for 2016. The company continues to expect U.S. Eylea net sales to grow 20–25% year over year.
REGENERON PHARM Price
REGENERON PHARM Price | REGENERON PHARM Quote
Check back later for our full write up on this Regeneron earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>